Relmada Therapeutics (RLMD) Projected to Post Earnings on Thursday

Relmada Therapeutics (NASDAQ:RLMD) is expected to post its Q4 2025 results after the market closes on Thursday, March 19th. Analysts expect Relmada Therapeutics to post earnings of ($0.14) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 19, 2026 at 4:30 PM ET.

Relmada Therapeutics Stock Performance

Shares of RLMD stock traded down $0.11 during trading hours on Friday, reaching $6.04. The company had a trading volume of 228,266 shares, compared to its average volume of 1,555,354. Relmada Therapeutics has a 12-month low of $0.24 and a 12-month high of $7.51. The company has a market capitalization of $442.77 million, a price-to-earnings ratio of -3.35 and a beta of 0.72. The stock has a fifty day moving average of $4.28 and a 200-day moving average of $3.34.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Jefferies Financial Group began coverage on Relmada Therapeutics in a report on Monday, December 22nd. They issued a “buy” rating and a $9.00 target price for the company. Mizuho raised shares of Relmada Therapeutics from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $1.00 to $10.00 in a research report on Wednesday, November 19th. Lucid Cap Mkts raised shares of Relmada Therapeutics to a “strong-buy” rating in a report on Monday, March 2nd. Zacks Research upgraded shares of Relmada Therapeutics to a “hold” rating in a research report on Tuesday, January 27th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Relmada Therapeutics in a research note on Wednesday, January 28th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Relmada Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

Insider Buying and Selling at Relmada Therapeutics

In other Relmada Therapeutics news, CFO Maged Shenouda acquired 11,665 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was purchased at an average cost of $4.12 per share, with a total value of $48,059.80. Following the transaction, the chief financial officer owned 800,000 shares of the company’s stock, valued at $3,296,000. This trade represents a 1.48% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 20.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of RLMD. Goldman Sachs Group Inc. acquired a new stake in shares of Relmada Therapeutics during the first quarter valued at about $33,000. XTX Topco Ltd acquired a new position in shares of Relmada Therapeutics in the 2nd quarter worth approximately $28,000. Marshall Wace LLP purchased a new position in shares of Relmada Therapeutics during the 2nd quarter worth approximately $93,000. Jane Street Group LLC purchased a new position in shares of Relmada Therapeutics during the 2nd quarter worth approximately $69,000. Finally, LMR Partners LLP acquired a new stake in Relmada Therapeutics in the 2nd quarter valued at approximately $33,000. Hedge funds and other institutional investors own 45.24% of the company’s stock.

Relmada Therapeutics Company Profile

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.